To explore the role and value of radical treatment of Helicobacter pylori in patients with gastric cancer complicated with Helicobacter pylori infection. Methods: From January 2022 to January 2023, 152 patients with gastric cancer complicated with Helicobacter pylori infection who were treated in our hospital were included in this study by random number table method. According to whether each patient received radical treatment based on Helicobacter pylori infection while receiving chemotherapy treatment, they were divided into the control group of single chemotherapy treatment and the observation group of combined radical treatment of Helicobacter pylori. The difference of treatment indexes between the two groups was analyzed. Results: The effective rate of treatment in the observation group was 88.16%, the total adverse reaction rate was 39.47%, and the treatment satisfaction rate was 93.42%; The effective rate of treatment in the control group was 78.95%, the total adverse reaction rate was 68.42%, and the treatment satisfaction rate was 82.89%. The difference was statistically significant (P<0.05). Conclusion: For patients with gastric cancer complicated with Helicobacter pylori infection, while receiving chemotherapy for gastric cancer, radical treatment for Helicobacter pylori can significantly improve the effective rate of clinical symptom relief of disease treatment, reduce the incidence of adverse reactions during various treatments, and improve the overall satisfaction of patients and their families with treatment.
Read full abstract